1. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial
- Author
-
Li Tao Zhang, Jong Kwan Park, Chen Zhao, Yu Seob Shin, Jae Hyung You, and In Sung Choi
- Subjects
Male ,Tamsulosin ,medicine.medical_specialty ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,urologic and male genital diseases ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Lower Urinary Tract Symptoms ,Randomized controlled trial ,law ,Lower urinary tract symptoms ,benign prostate hyperplasia ,medicine ,Humans ,Prospective Studies ,Aged ,Original Research ,Transurethral resection of the prostate ,Aged, 80 and over ,combination ,Sulfonamides ,solifenacin ,Solifenacin ,Urinary Bladder, Overactive ,business.industry ,Transurethral Resection of Prostate ,Solifenacin Succinate ,General Medicine ,Middle Aged ,transurethral resection of the prostate ,medicine.disease ,Treatment Outcome ,Overactive bladder ,Clinical Interventions in Aging ,030220 oncology & carcinogenesis ,Quality of Life ,Urological Agents ,Drug Therapy, Combination ,International Prostate Symptom Score ,Geriatrics and Gerontology ,business ,Tamsulosin hydrochloride ,medicine.drug - Abstract
Yu Seob Shin,1,* Li Tao Zhang,1,* Jae Hyung You,1 In Sung Choi,1 Chen Zhao,2 Jong Kwan Park1 1Department of Urology, Chonbuk National University and Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute and Medical Device Clinical Trial Center of Chonbuk National University, Jeonju, Republic of Korea; 2Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Shanghai Institute of Andrology, Shanghai, People’s Republic of China *These authors contributed equally tothis work Objective: The objective of this study was to evaluate the safety and efficacy of tamsulosin hydrochloride 0.2mg (TAM) and its combination with solifenacin succinate 5mg (SOL) after transurethral resection of the prostate (TURP).Patients and methods: The patients were randomized into three groups: TURP (group 1), TURP plus TAM (group 2), and TURP plus TAM + SOL (group 3). Patients in group 2 and group 3 received medication for 4weeks. The primary efficacy end points were the mean change in total International Prostate Symptom Score (IPSS) and IPSS subscores. The secondary end points included quality-of-life score, Overactive Bladder Symptom Score, and short-form voiding and storage score of International Continence Society.Results: In total, 37 men (31.8%) in group 1, 37 men (31.8%) in group 2, and 42 men (36.2%) in group 3 completed the study. In total IPSS, no significant improvement was seen from baseline to the end of treatment in groups 2 and 3 compared with group 1. However, in group 2, the decrement in the IPSS storage score was smaller than group 1 (P=0.02), and in group 3, the decrement in the IPSS voiding score was smaller than group 1 (P=0.05). In groups 2 and 3 compared with group 1, improvements in the quality of life score, total score of Overactive Bladder Symptom Score, and short-form voiding score and storage score of International Continence Society were not statistically significant.Conclusion: Treatment with TAM and combination of TAM and SOL did not have significant additional benefits for lower urinary tract symptoms during the early recovery period afterTURP. Keywords: benign prostate hyperplasia, tamsulosin, solifenacin, combination, transurethral resection of the prostate
- Published
- 2016
- Full Text
- View/download PDF